Baseline characteristics for patients enrolled in the expansion cohorts (parts B and D)
| . | Relatlimab monotherapy (240 mg; part B) . | Nivolumab plus relatlimab (240 mg/160 mg; part D) . | |||||
|---|---|---|---|---|---|---|---|
| CLL (n = 2) . | DLBCL (n = 2) . | IL (n = 4) . | HL∗ (n = 3) . | Anti–PD-(L)1–naive HL∗ (n = 21) . | Anti–PD-(L)1–progressed HL∗ (n = 20) . | DLBCL (n = 15) . | |
| Age, median (range), y | 67.5 (67-68) | 64.5 (39-90) | 62.0 (53-69) | 24.0 (20-47) | 35.0 (19-64) | 35.5 (25-74) | 73.0 (50-85) |
| Sex, n (%) | |||||||
| Male | 0 | 1 (50.0) | 4 (100.0) | 3 (100.0) | 15 (71.4) | 10 (50.0) | 10 (66.7) |
| Female | 2 (100.0) | 1 (50.0) | 0 | 0 | 6 (28.6) | 10 (50.0) | 5 (33.3) |
| Race, n (%) | |||||||
| White | 1 (50.0) | 2 (100.0) | 3 (75.0) | 3 (100.0) | 13 (61.9) | 16 (80.0) | 14 (93.3) |
| Black/African American | 1 (50.0) | 0 | 0 | 0 | 2 (9.5) | 1 (5.0) | 0 |
| Asian | 0 | 0 | 0 | 0 | 2 (9.5) | 2 (10.0) | 1 (6.7) |
| Native Hawaiian/other Pacific Islander | 0 | 0 | 0 | 0 | 1 (4.8) | 0 | 0 |
| Other | 0 | 0 | 1 (25.0) | 0 | 3 (14.3) | 1 (5.0) | 0 |
| Ethnicity, n (%) | |||||||
| Hispanic or Latino | 0 | 0 | 0 | 0 | 1 (4.8) | 1 (5.0) | 0 |
| Not Hispanic or Latino | 2 (100.0) | 2 (100.0) | 4 (100.0) | 3 (100.0) | 20 (95.2) | 19 (95.0) | 15 (100.0) |
| Country, n (%) | |||||||
| Canada | 0 | 0 | 0 | 0 | 1 (4.8) | 6 (30.0) | 0 |
| United States | 2 (100.0) | 2 (100.0) | 4 (100.0) | 3 (100.0) | 20 (95.2) | 14 (70.0) | 15 (100.0) |
| ECOG PS, n (%) | |||||||
| 0 | 2 (100.0) | 2 (100.0) | 3 (75.0) | 2 (66.7) | 17 (81.0) | 10 (50.0) | 4 (26.7) |
| 1 | 0 | 0 | 1 (25.0) | 1 (33.3) | 4 (19.0) | 10 (50.0) | 10 (66.7) |
| 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (6.7) |
| Prior therapy regimens, n (%) | |||||||
| 1 | 0 | 1 (50.0) | 1 (25.0) | 0 | 5 (23.8) | 0 | 0 |
| 2 | 0 | 0 | 1 (25.0) | 0 | 6 (28.6) | 3 (15.0) | 3 (20.0) |
| 3 | 0 | 0 | 1 (25.0) | 1 (33.3) | 8 (38.1) | 1 (5.0) | 1 (6.7) |
| 4 | 1 (50.0) | 0 | 0 | 1 (33.3) | 1 (4.8) | 3 (15.0) | 7 (46.7) |
| ≥5 | 1 (50.0) | 1 (50.0) | 1 (25.0) | 1 (33.3) | 1 (4.8) | 13 (65.0) | 4 (26.7) |
| Previous anti–PD-(L)1 therapy, n (%) | |||||||
| 0 | 0 | 0 | 0 | 1 (33.3) | 21 (100.0) | 0 | 14 (93.3) |
| 1 | 0 | 1 (50.0) | 2 (50.0) | 0 | 0 | 4 (20.0) | 1 (6.7) |
| >1 | 2 (100.0) | 1 (50.0) | 2 (50.0) | 2 (66.7) | 0 | 16 (80.0) | 0 |
| Previous brentuximab therapy, n (%) | 0 | 0 | 0 | 2 (66.7) | 12 (57.1) | 15 (75.0) | 0 |
| Previous stem cell transplant, n (%) | 0 | 0 | 2 (50.0) | 2 (66.7) | 6 (28.6) | 13 (65.0) | 7 (46.7) |
| Sum of the product of diameters, median (range), mm2 | N/A | N/A | N/A | N/A | 1060.0 (0-5576) | 3 265.5 (551-26 758) | 1186.5 (155-8392) |
| . | Relatlimab monotherapy (240 mg; part B) . | Nivolumab plus relatlimab (240 mg/160 mg; part D) . | |||||
|---|---|---|---|---|---|---|---|
| CLL (n = 2) . | DLBCL (n = 2) . | IL (n = 4) . | HL∗ (n = 3) . | Anti–PD-(L)1–naive HL∗ (n = 21) . | Anti–PD-(L)1–progressed HL∗ (n = 20) . | DLBCL (n = 15) . | |
| Age, median (range), y | 67.5 (67-68) | 64.5 (39-90) | 62.0 (53-69) | 24.0 (20-47) | 35.0 (19-64) | 35.5 (25-74) | 73.0 (50-85) |
| Sex, n (%) | |||||||
| Male | 0 | 1 (50.0) | 4 (100.0) | 3 (100.0) | 15 (71.4) | 10 (50.0) | 10 (66.7) |
| Female | 2 (100.0) | 1 (50.0) | 0 | 0 | 6 (28.6) | 10 (50.0) | 5 (33.3) |
| Race, n (%) | |||||||
| White | 1 (50.0) | 2 (100.0) | 3 (75.0) | 3 (100.0) | 13 (61.9) | 16 (80.0) | 14 (93.3) |
| Black/African American | 1 (50.0) | 0 | 0 | 0 | 2 (9.5) | 1 (5.0) | 0 |
| Asian | 0 | 0 | 0 | 0 | 2 (9.5) | 2 (10.0) | 1 (6.7) |
| Native Hawaiian/other Pacific Islander | 0 | 0 | 0 | 0 | 1 (4.8) | 0 | 0 |
| Other | 0 | 0 | 1 (25.0) | 0 | 3 (14.3) | 1 (5.0) | 0 |
| Ethnicity, n (%) | |||||||
| Hispanic or Latino | 0 | 0 | 0 | 0 | 1 (4.8) | 1 (5.0) | 0 |
| Not Hispanic or Latino | 2 (100.0) | 2 (100.0) | 4 (100.0) | 3 (100.0) | 20 (95.2) | 19 (95.0) | 15 (100.0) |
| Country, n (%) | |||||||
| Canada | 0 | 0 | 0 | 0 | 1 (4.8) | 6 (30.0) | 0 |
| United States | 2 (100.0) | 2 (100.0) | 4 (100.0) | 3 (100.0) | 20 (95.2) | 14 (70.0) | 15 (100.0) |
| ECOG PS, n (%) | |||||||
| 0 | 2 (100.0) | 2 (100.0) | 3 (75.0) | 2 (66.7) | 17 (81.0) | 10 (50.0) | 4 (26.7) |
| 1 | 0 | 0 | 1 (25.0) | 1 (33.3) | 4 (19.0) | 10 (50.0) | 10 (66.7) |
| 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (6.7) |
| Prior therapy regimens, n (%) | |||||||
| 1 | 0 | 1 (50.0) | 1 (25.0) | 0 | 5 (23.8) | 0 | 0 |
| 2 | 0 | 0 | 1 (25.0) | 0 | 6 (28.6) | 3 (15.0) | 3 (20.0) |
| 3 | 0 | 0 | 1 (25.0) | 1 (33.3) | 8 (38.1) | 1 (5.0) | 1 (6.7) |
| 4 | 1 (50.0) | 0 | 0 | 1 (33.3) | 1 (4.8) | 3 (15.0) | 7 (46.7) |
| ≥5 | 1 (50.0) | 1 (50.0) | 1 (25.0) | 1 (33.3) | 1 (4.8) | 13 (65.0) | 4 (26.7) |
| Previous anti–PD-(L)1 therapy, n (%) | |||||||
| 0 | 0 | 0 | 0 | 1 (33.3) | 21 (100.0) | 0 | 14 (93.3) |
| 1 | 0 | 1 (50.0) | 2 (50.0) | 0 | 0 | 4 (20.0) | 1 (6.7) |
| >1 | 2 (100.0) | 1 (50.0) | 2 (50.0) | 2 (66.7) | 0 | 16 (80.0) | 0 |
| Previous brentuximab therapy, n (%) | 0 | 0 | 0 | 2 (66.7) | 12 (57.1) | 15 (75.0) | 0 |
| Previous stem cell transplant, n (%) | 0 | 0 | 2 (50.0) | 2 (66.7) | 6 (28.6) | 13 (65.0) | 7 (46.7) |
| Sum of the product of diameters, median (range), mm2 | N/A | N/A | N/A | N/A | 1060.0 (0-5576) | 3 265.5 (551-26 758) | 1186.5 (155-8392) |
CLL, chronic lymphocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group performance status; IL, indolent lymphoma; N/A, not available.
Most patients had classic HL; 2 patients with nodular lymphocyte–predominant HL were included in part D (1 in PD-(L)1–progressed and 1 in PD-(L)1–naive).